These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 24052234)

  • 1. Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody.
    Omidfar K; Amjad Zanjani FS; Hagh AG; Azizi MD; Rasouli SJ; Kashanian S
    Mol Biol Rep; 2013 Dec; 40(12):6737-45. PubMed ID: 24052234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
    Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
    Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).
    Zhu H; Zhao L; Li Z; Wen B; Qiu C; Liu M; Xu Z; Hu S; Li H
    Protein Expr Purif; 2019 May; 157():57-62. PubMed ID: 30735705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
    Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
    Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus.
    Omidfar K; Rasaee MJ; Modjtahedi H; Forouzandeh M; Taghikhani M; Bakhtiari A; Paknejad M; Kashanian S
    Tumour Biol; 2004; 25(4):179-87. PubMed ID: 15557755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival.
    Tabtimmai L; Suphakun P; Srisook P; Kiriwan D; Phanthong S; Kiatwuthinon P; Chaicumpa W; Choowongkomon K
    J Cell Biochem; 2019 Oct; 120(10):18077-18087. PubMed ID: 31172597
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Piramoon M; Hosseinimehr SJ; Omidfar K; Noaparast Z; Abedi SM
    Chem Biol Drug Des; 2017 Apr; 89(4):498-504. PubMed ID: 27650045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-Targeted Nanobody Functionalized Polymeric Micelles Loaded with mTHPC for Selective Photodynamic Therapy.
    Liu Y; Scrivano L; Peterson JD; Fens MHAM; Hernández IB; Mesquita B; Toraño JS; Hennink WE; van Nostrum CF; Oliveira S
    Mol Pharm; 2020 Apr; 17(4):1276-1292. PubMed ID: 32142290
    [No Abstract]   [Full Text] [Related]  

  • 10. A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo.
    Xu Z; Qiu C; Wen B; Wang S; Zhu L; Zhao L; Li H
    Biochem Biophys Res Commun; 2021 Apr; 548():78-83. PubMed ID: 33636638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours.
    Wang L; Zhang G; Qin L; Ye H; Wang Y; Long B; Jiao Z
    Recent Pat Anticancer Drug Discov; 2020; 15(3):200-211. PubMed ID: 32885759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and functional insight into anti-EGFR nanobody: Theranostic implications for malignancies.
    Tripathy RK; Pande AH
    Life Sci; 2024 May; 345():122593. PubMed ID: 38554946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel anti-EGFR nanobody by phage display and its distinct paratope and epitope via homology modeling and molecular docking.
    Xi X; Sun W; Su H; Zhang X; Sun F
    Mol Immunol; 2020 Dec; 128():165-174. PubMed ID: 33130376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
    Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
    Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A camelid nanobody against EGFR was easily obtained through refolding of inclusion body expressed in Escherichia coli.
    Xu L; Song X; Jia L
    Biotechnol Appl Biochem; 2017 Nov; 64(6):895-901. PubMed ID: 28853185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor.
    Behdani M; Zeinali S; Khanahmad H; Karimipour M; Asadzadeh N; Azadmanesh K; Khabiri A; Schoonooghe S; Habibi Anbouhi M; Hassanzadeh-Ghassabeh G; Muyldermans S
    Mol Immunol; 2012 Feb; 50(1-2):35-41. PubMed ID: 22208996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of a mono-biotinylated EGFR nanobody in the E. coli periplasm using the pET22b vector.
    Noor A; Walser G; Wesseling M; Giron P; Laffra AM; Haddouchi F; De Grève J; Kronenberger P
    BMC Res Notes; 2018 Oct; 11(1):751. PubMed ID: 30348204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Ahmadvand D; Mahboudi F; Sharifzadeh Z
    Exp Cell Res; 2012 Jun; 318(10):1112-24. PubMed ID: 22440788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
    Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
    Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.